The high prevalence of cardiovascular diseases in Ukraine and the world ensures a consistently high demand for hypolipidemic drugs. The rational formation of the pharmacy range of these drugs is a key task for the pharmaceutical industry and affects the effectiveness of therapy, patient adherence and economic availability of treatment. Aim. To analyze the most in-demand and physically available hypolipidemic drugs in the pharmaceutical market of Ukraine, taking into account their economic and physical accessibility for the rational formation of used pharmacy range. Materials and methods. The study used the content analysis methods to systematically collect and process data on lipid-lowering drugs. The drugs were grouped according to active ingredients, manufacturers, and average retail prices to identify key trends in the range formation. Economic accessibility was assessed based on the cost of the defined daily dose (DDD) for the main indication in adults, which allowed to compare treatment costs between drugs from different manufacturers. Data were collected in June 2025 and from scientific publications covering the period of 2018–2025. Results and discussion. A total of 319 lipid-lowering drugs registered in Ukraine as of June 1, 2025, were analyzed. Statins accounted for the largest share (84 %), confirming their dominance in the treatment of dyslipidemia. Foreign-manufactured drugs comprised 83 % of the range, while domestic medicines accounted for only 17 %. Monotherapy drugs predominated in the market (86 %), whereas combined drugs made up only 14 %. The example of the drug “Tricor®” demonstrated significant differences in the physical availability of hypolipidemic drugs in different cities of Ukraine. The analysis of economic accessibility using the DDD cost method revealed variability in the cost – from 1.15 UAH to 7.85 UAH per DDD – and the monthly cost of lipid-lowering therapy ranged from 34.50 UAH to 235.50 UAH. Conclusions. The analysis conducted will allow pharmacy managers and pharmacists to make informed decisions regarding the management of the hypolipidemic drug range, taking into account both physical availability and economic accessibility.
Ткачова et al. (Thu,) studied this question.